Calidi Biotherapeutics (CLDI): Price-to-Projected Revenue Ratio

Public company logo of Calidi Biotherapeutics Inc. (CLDI)

Calidi Biotherapeutics (CLDI) success is based on R&D control and passing FDA trials amid stable liquidity. On the GURU.Markets platform, the projected price-to-sales valuation reflects current dynamics, where the parameter value reaches . Development relies on the NeuroNova ecosystem with exclusive clinic supply, while operational activities comply with ESG standards for bio-waste disposal and laboratory energy efficiency.

Calidi Biotherapeutics, Inc. - CLDI Market Cap to Expected Sales Ratio (period 07/04/2022 - 11/13/2026)

Analytical breakdowns for Calidi Biotherapeutics

- current price and projected stock value:
Stock Price Calidi Biotherapeutics, Inc.|CLDI - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Value Calidi Biotherapeutics|CLDI - Total Company Value
- book value of equity indicators:
Book Value per Share Calidi Biotherapeutics|CLDI - Book Valuation of Business|Market Capitalization to Book Value Ratio calidibio.com|CLDI - Total Business Assets
- business debt structure and liquidity details:
Total Debt to Capital Calidi Biotherapeutics|CLDI - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio Calidi Biotherapeutics, Inc.|CLDI - Aggregate Debt Obligations|Debts to Book Capitalization Calidi Biotherapeutics|CLDI - Company Long-Term Debt|Company Short-Term Debts Calidi Biotherapeutics|Quick Liquidity calidibio.com
- financial results and valuation multiples details:
CLDI - Company Net Income|Future Profit Calidi Biotherapeutics|CLDI - Market Price to Net Income Ratio|Forward P/E Multiple Calidi Biotherapeutics, Inc.|CLDI - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Calidi Biotherapeutics|CLDI - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Calidi Biotherapeutics|CLDI - Earnings per share for the trailing year|Quarterly EPS earnings growth calidibio.com|CLDI - Earnings growth in current year|Net earnings per share growth forecast for next year Calidi Biotherapeutics
- sales volume and revenue indicators:
CLDI - Company Annual Revenue|Projected Sales Volume Calidi Biotherapeutics, Inc.|CLDI - Price to Sales|Forward Price-to-Revenue Multiple Calidi Biotherapeutics
Summary company analysis:Calidi Bio CLDI
Product sample of Calidi Biotherapeutics Inc.

Forward P/S measures a company's market value relative to expected revenue, allowing for an assessment of the premium paid for future cash flows. By analyzing the forward P/S metric, an investor can observe capitalization dynamics within the context of risks facing Calidi Biotherapeutics (CLDI), where geopolitical barriers to technology exports could slow drug commercialization and adjust sales forecasts.

Who Calidi Biotherapeutics competes with

Forward P/S Multiple ONC (BeiGene)|Forward P/S Multiple Halozyme Therapeutics, Inc. HALO|RVMD - Price-to-Projected Revenue Ratio|AAPG: Price-to-Projected Revenue Ratio|CGON: Forward P/S Multiple|URGN - Market Cap to Expected Sales Ratio|BCAX (Bicara Therapeutics) - Forward P/S Multiple|Market Cap to Projected Revenue PSNL (Personalis Inc)|Forward P/S Multiple ERAS|Market Cap to Expected Sales Ratio Delcath Corp|Y-mAbs Therapeutics - Forward Price-to-Revenue Multiple|Forward Price to Sales AURA|Candel - Forward P/S Multiple|ARAY: Price-to-Projected Revenue Ratio|SLS: Forward P/S Multiple|ACTU - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Citius Oncology, Inc.|Market Cap to Future Revenue Ratio TuHURA HURA|Forward Price-to-Revenue Multiple TARA (Protara Therapeutics, Inc.)|Price to Expected Revenue Ratio FATE|Forward P/S Multiple WHWK (Aadi Bioscience)|Forward Price to Sales TCRX|Champions Oncology Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio XBiotech Inc.|cel-sci.com (CVM) - Price-to-Projected Revenue Ratio|OS Therapies Inc. - Forward Price to Sales|RADX (Radiopharm Theranostics Limited) - Forward P/S Multiple|Forward P/S Multiple Artiva|Price-to-Projected Revenue Ratio Adlai Nortye Ltd. (ANL)|VERU: Future Price to Revenue|Forward P/S Multiple TPST (Tempest Therapeutics, Inc.)|Xilio Therapeutics Inc (XLO) - Market Cap to Future Revenue Ratio|RENB: Forward Price-to-Revenue Multiple|MURA - Forward P/S Multiple|KAPA (kairospharma.com) - Forward Price-to-Revenue Multiple|OKUR: Price to Expected Revenue Ratio|GDTC (CytoMed Therapeutics Ltd) - Forward P/S Multiple|Curis Corp (CRIS) - Market Cap to Expected Sales Ratio|Forward P/S Multiple APLM|Forward Price-to-Revenue Multiple Tharimmune Corporation THAR|Price-to-Projected Revenue Ratio Advanced Biomed ADVB|Market Cap to Expected Sales Ratio genprex.com (GNPX)|Sunshine Biopharma, Inc. - Forward P/S Multiple|Xenetic Biosciences (XBIO) - Forward Price-to-Revenue Multiple|Salarius (SLRX) - Price-to-Projected Revenue Ratio|PPBT (Kitov Pharma) - Price-to-Projected Revenue Ratio|AONC (American Oncology Network Inc) - Forward P/S Multiple|Market Cap to Projected Revenue BGNE (beigene.com)|Forward P/S Multiple CKPT|Market Cap to Expected Sales Ratio elevationoncology.com|Forward P/S Multiple ICAD (iCAD)|IKNA - Forward Price-to-Revenue Multiple|Notable Labs, Ltd. - Forward P/S Multiple|VIRX - Forward P/S Multiple|MorphoSys (MOR) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue NAYA|AAPGV (Ascentage Pharma Group Ltd) - Forward P/S Multiple